Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and reduced health-related quality of life. Findings from clinical trials have demonstrated the effectiveness of dupilumab in CRSwNP, although real-world evidence is still limited. Methods: This Phase IV real-life, observational, multicenter study assessed the effectiveness and safety of dupilumab in patients with severe uncontrolled CRSwNP (n = 648) over the first year of treatment. We collected data at baseline and after 1, 3, 6, 9, and 12 months of follow-up. We focused on nasal polyps score (NPS), symptoms, and olfactory function. We stratified outcomes by comorbidities, previous surgery, and adherence to intranasal corticosteroids, and examined the success rates based on current guidelines, as well as potential predictors of response at each timepoint. Results: We observed a significant decrease in NPS from a median value of 6 (IQR 5–6) at baseline to 1.0 (IQR 0.0–2.0) at 12 months (p <.001), and a significant decrease in Sino-Nasal Outcomes Test-22 (SNOT-22) from a median score of 58 (IQR 49–70) at baseline to 11 (IQR 6–21; p <.001) at 12 months. Sniffin' Sticks scores showed a significant increase over 12 months (p <.001) compared to baseline. The results were unaffected by concomitant diseases, number of previous surgeries, and adherence to topical steroids, except for minor differences in rapidity of action. An excellent-moderate response was observed in 96.9% of patients at 12 months based on EPOS 2020 criteria. Conclusions: Our findings from this large-scale real-life study support the effectiveness of dupilumab as an add-on therapy in patients with severe uncontrolled CRSwNP in reducing polyp size and improving the quality of life, severity of symptoms, nasal congestion, and smell.

Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL) / De Corso, E.; Pasquini, E.; Trimarchi, M.; La Mantia, I.; Pagella, F.; Ottaviano, G.; Garzaro, M.; Pipolo, C.; Torretta, S.; Seccia, V.; Cantone, E.; Ciofalo, A.; Lucidi, D.; Fadda, G. L.; Pafundi, P. C.; Settimi, S.; Montuori, C.; Anastasi, F.; Pagliuca, G.; Ghidini, A.; Cavaliere, C.; Maffei, M.; Bussu, F.; Gallo, S.; Mauritz Canevari, F. R.; Paludetti, G.; Galli, J.; Spanu, C.; Porru, D. P.; Lo Verde, S.; Corbo, M.; Cantiani, A.; Furno, D.; D'Agostino, G.; D'Auria, L. M.; De Maio, G.; Di Bella, G. A.; Penazzi, D.; Mele, D. A.; Di Cesare, T.; Andrea, R.; Tanzini, U.; Saccardo, T.; Roccuzzo, G.; Cipolla, F.; Ragusa, M.; Grigaliute, E.; Ciufelli, M. A.; Roncadi, L.; Rizzo, D.; De Vita, C.; Farneti, P.; Todero, G.; Cristofani-Mencacci, L.; Statuti, E.; Cavallo, G.; Urbanelli, A.; Ferrella, F.; Arnone, F.; Di Nola, C.; Pignataro, L.; Nava, N.; Russo, P.; Savastano, V.; Masieri, S.; Dell'Era, V.; Valletti, P. A.; Sovardi, F.; Siragusa, V.; Clemenzi, V.; Stolfa, A.; Simoni, E.; Astolfi, L.. - In: ALLERGY. - ISSN 0105-4538. - 78:10(2023), pp. 2669-2683. [10.1111/all.15772]

Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL)

Pagliuca G.;Bussu F.;Galli J.;D'Agostino G.;Cipolla F.;Rizzo D.;Cavallo G.;
2023-01-01

Abstract

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and reduced health-related quality of life. Findings from clinical trials have demonstrated the effectiveness of dupilumab in CRSwNP, although real-world evidence is still limited. Methods: This Phase IV real-life, observational, multicenter study assessed the effectiveness and safety of dupilumab in patients with severe uncontrolled CRSwNP (n = 648) over the first year of treatment. We collected data at baseline and after 1, 3, 6, 9, and 12 months of follow-up. We focused on nasal polyps score (NPS), symptoms, and olfactory function. We stratified outcomes by comorbidities, previous surgery, and adherence to intranasal corticosteroids, and examined the success rates based on current guidelines, as well as potential predictors of response at each timepoint. Results: We observed a significant decrease in NPS from a median value of 6 (IQR 5–6) at baseline to 1.0 (IQR 0.0–2.0) at 12 months (p <.001), and a significant decrease in Sino-Nasal Outcomes Test-22 (SNOT-22) from a median score of 58 (IQR 49–70) at baseline to 11 (IQR 6–21; p <.001) at 12 months. Sniffin' Sticks scores showed a significant increase over 12 months (p <.001) compared to baseline. The results were unaffected by concomitant diseases, number of previous surgeries, and adherence to topical steroids, except for minor differences in rapidity of action. An excellent-moderate response was observed in 96.9% of patients at 12 months based on EPOS 2020 criteria. Conclusions: Our findings from this large-scale real-life study support the effectiveness of dupilumab as an add-on therapy in patients with severe uncontrolled CRSwNP in reducing polyp size and improving the quality of life, severity of symptoms, nasal congestion, and smell.
2023
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL) / De Corso, E.; Pasquini, E.; Trimarchi, M.; La Mantia, I.; Pagella, F.; Ottaviano, G.; Garzaro, M.; Pipolo, C.; Torretta, S.; Seccia, V.; Cantone, E.; Ciofalo, A.; Lucidi, D.; Fadda, G. L.; Pafundi, P. C.; Settimi, S.; Montuori, C.; Anastasi, F.; Pagliuca, G.; Ghidini, A.; Cavaliere, C.; Maffei, M.; Bussu, F.; Gallo, S.; Mauritz Canevari, F. R.; Paludetti, G.; Galli, J.; Spanu, C.; Porru, D. P.; Lo Verde, S.; Corbo, M.; Cantiani, A.; Furno, D.; D'Agostino, G.; D'Auria, L. M.; De Maio, G.; Di Bella, G. A.; Penazzi, D.; Mele, D. A.; Di Cesare, T.; Andrea, R.; Tanzini, U.; Saccardo, T.; Roccuzzo, G.; Cipolla, F.; Ragusa, M.; Grigaliute, E.; Ciufelli, M. A.; Roncadi, L.; Rizzo, D.; De Vita, C.; Farneti, P.; Todero, G.; Cristofani-Mencacci, L.; Statuti, E.; Cavallo, G.; Urbanelli, A.; Ferrella, F.; Arnone, F.; Di Nola, C.; Pignataro, L.; Nava, N.; Russo, P.; Savastano, V.; Masieri, S.; Dell'Era, V.; Valletti, P. A.; Sovardi, F.; Siragusa, V.; Clemenzi, V.; Stolfa, A.; Simoni, E.; Astolfi, L.. - In: ALLERGY. - ISSN 0105-4538. - 78:10(2023), pp. 2669-2683. [10.1111/all.15772]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/324231
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 22
  • ???jsp.display-item.citation.isi??? ND
social impact